Search the Newsreel

Barinthus Biotherapeutics PLC (BRNS) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Barinthus Biotherapeutics PLC (BRNS), noting its current score of 1.98, ranking 247 out of 386 in the Biotechnology & Medical Research industry. The company's beta value is -0.39, indicating it tends to underperform in rising markets but …

LNTH Stock Drops After-Hours As Curium's $7B Offer Comes In Below Market Value

Shares of Lantheus Holdings Inc. (LNTH) dropped 3% in after-hours trading following reports that Curium is in advanced talks to acquire the radiopharmaceutical firm for $7 billion. The offer, which includes an upfront payment of roughly $102 per share plus contingent value rights, is …

Curium in talks to buy Lantheus Holdings for about $7B - Bloomberg (LNTH:NASDAQ)

Curium, backed by CapVest Partners, is reportedly in advanced discussions to acquire radiopharma company Lantheus Holdings (LNTH) for approximately $7 billion. The deal is expected to be announced soon, with Curium offering an upfront payment of around $102 per share and an additional $12.50 …

Barinthus Biotherapeutics PLC (BRNS) Institutional Confidence

Barinthus Biotherapeutics PLC (BRNS) has an institutional shareholding score of 3.00, placing it 191st out of 384 in the Biotechnology & Medical Research industry. The institutional shareholding proportion decreased by 10.63% quarter-over-quarter to 40.87%. James Simons is the largest institutional shareholder, holding 0.37% of …

LITB|LightInTheBox Holding Co Ltd|Price:3.150|Chg%:-0.140

This article provides a financial overview of LightInTheBox Holding Co Ltd (LITB), detailing its income statement, balance sheet, and cash flow statement. It highlights the company's latest earnings release, projecting EPS and revenue, and presents quarterly and annual financial indicators. The report also includes …

LightInTheBox Holding Co Ltd (LITB) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article details the dividend and stock split history for LightInTheBox Holding Co Ltd (LITB). It shows that LITB has not distributed any dividends in the past five years. The company has a series of "Merger" type stock splits recorded for August 27, 2024, …

Lantheus Holdings Inc (LNTH) Cash Flow

This article provides a detailed cash flow statement for Lantheus Holdings Inc (LNTH), broken down into operating, investing, and financing activities on a quarterly and annual basis. It includes historical data spanning many years, along with year-over-year percentage changes. The piece also features a …

Octagon Capital Advisors LP Has $163.36 Million Position in Dianthus Therapeutics, Inc. $DNTH

Octagon Capital Advisors LP reduced its stake in Dianthus Therapeutics, Inc. by 19.4% in the first quarter, yet it remains its largest holding, valued at $163.36 million. Despite insider selling, institutional ownership in DNTH is significant, with several firms increasing their positions. Analysts maintain …

Lantheus Holdings, Inc. (LNTH) Stock Analysis: Exploring a 7.17% Potential Upside in the Healthcare Sector

Lantheus Holdings Inc. (LNTH), a healthcare company specializing in diagnostic and therapeutic products, shows a potential upside of 7.17% according to analyst ratings. The company maintains a market capitalization of $6.82 billion, a forward P/E of 16.64, and strong financial health with $421.7 million …

Curium in Talks to Acquire Lantheus For $7 Billion

Curium is reportedly in discussions to acquire Lantheus Holdings, Inc. for $7 billion. This potential acquisition follows recent news of Lantheus weighing a sale after Curium's initial offer. Lantheus specializes in radiopharmaceuticals for diagnostics and treatment in areas like oncology, neurology, and cardiology.

Why Did Northrop Grumman (NOC) Fall After Raising Its 2026 Forecast?

Northrop Grumman Corporation (NYSE:NOC) beat quarterly expectations, secured $20 billion in net awards, reported record backlog, and raised its 2026 sales and MTM-adjusted earnings forecasts. Yet the shares closed 2.23% lower at $512.29 on July 21. The contradiction becomes clearer when the quality of …

Dianthus Therapeutics Inc (DNTH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides details on Dianthus Therapeutics Inc's (DNTH) revenue breakdown. It indicates that relevant data for business segments and profit contribution have not yet been disclosed by the company for FY2025, FY2025Q4, and FY2025Q3. The company only reports a United States revenue proportion …

LightInTheBox Holding Co Ltd (LITB) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for LightInTheBox Holding Co Ltd (LITB), detailing future EPS and revenue growth estimates. It includes current stock information such as market cap, P/E ratio, and recent price movements, along with a peer comparison. The financial forecasting section indicates …

Dianthus Therapeutics Inc (DNTH) Cash Flow

This article provides a detailed cash flow statement for Dianthus Therapeutics Inc (DNTH), including quarterly and annual data for operating, investing, and financing activities. It also defines key cash flow metrics and answers frequently asked questions regarding DNTH's cash flow performance, such as operating …

Barinthus Biotherapeutics PLC (BRNS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Barinthus Biotherapeutics PLC's (BRNS) dividend history and stock splits. It indicates that the company has not distributed any dividends over the past five years. The page also presents current stock pricing and market capitalization information for BRNS.

Dianthus Therapeutics, Inc. $DNTH Shares Bought by SummitTX Capital L.P.

Lantheus Holdings Inc (LNTH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Lantheus Holdings Inc (LNTH), detailing its performance by business segments such as PYLARIFY, DEFINITY, TechneLite, Strategic partnerships, and Neuraceq. It presents financial data across multiple fiscal years and quarters, highlighting each segment's revenue contribution. The report indicates …

LightInTheBox Holding Co., Ltd. Revenue Breakdown – NYSE:LITB

LightInTheBox Holding Co., Ltd. (NYSE: LITB) generated 224.30 million USD in total revenue last year. The Product Sales segment was the top-performing segment, contributing 617.24 million USD, and Europe was the largest regional contributor with 313.56 million USD in sales. The article provides a …

TradingKey

This article provides a detailed quarterly and annual cash flow statement for Barinthus Biotherapeutics PLC (BRNS), covering operating, investing, and financing activities from FY2020Q1 to FY2026Q1. It includes key financial figures such as net income, changes in working capital, capital expenditures, and free cash …

Anthem Biosciences sees Q1 revenue dip but maintains FY27 growth outlook

Gentherm Inc (THRM) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for Gentherm Inc (THRM) stock, showing its current trading price and recent performance. It also includes sections for analyst ratings and earnings information, although data for these sections is currently unavailable. The article is part of a …

SpaceX (SPCX) Launches Northrop Grumman Repair Mission And Opens A New Service Market

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Space Exploration Technologies (NasdaqGS:SPCX) launched Northrop Grumman's MRV-MEP satellite repair mission, focused on on-orbit …

Barinthus Biotherapeutics plc Sponsored ADR Revenue Breakdown – GETTEX:2AB

This page provides financial information for Barinthus Biotherapeutics plc Sponsored ADR (2AB) on Gettex, indicating no current trading activity. It lists various financial data points like statements, statistics, dividends, earnings, and segment performance. The content appears to be a stub or an informational page …

Barinthus Biotherapeutics plc (BRNS) stock price, news, quote and history

Barinthus Biotherapeutics plc (BRNS) is a biotechnology company focused on developing immunotherapies and vaccines. The article provides current stock price data, historical performance, key financial metrics, and analyst ratings, indicating a buy recommendation with a target price of $5.50. The company is developing treatments …

EcoSynthetix Inc. Revenue Breakdown – TSX:ECO

LightInTheBox Holding Co Ltd (LITB) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for LightInTheBox Holding Co Ltd (LITB), noting its current valuation score of 9.78, ranking first in the Textiles & Apparel industry. It highlights the company's current P/E ratio of 6.02, which is significantly below its recent high and …

Lantheus Holdings Inc Revenue Breakdown – XETR:0L8

Lantheus Holdings Inc (XETR:0L8) generated 1.31 billion EUR in revenue last year, with its top-performing segment, PYLARIFY, contributing 842.15 million EUR. The United States was the primary regional contributor, accounting for 1.24 billion EUR of the company's revenue. This financial breakdown highlights the company's …

Spruce Street Capital LP Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH

Spruce Street Capital LP significantly increased its stake in Dianthus Therapeutics (NASDAQ:DNTH) by 25.5% in the first quarter of 2026, holding 373,274 shares valued at $31.3 million. Despite recent insider sales totaling about $8.0 million, analysts maintain a "Moderate Buy" rating with an average …

LNTH|Lantheus Holdings Inc|Price:104.820|Chg%:+1.090

Lantheus Holdings Inc (LNTH) is trading at $104.82, up 1.05%, with a market cap of $6.82 billion. The company exhibits strong fundamentals and high growth potential, though its valuation is considered fairly valued within the Healthcare Equipment & Supplies industry. Analysts largely rate it …

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Analysts

Dianthus Therapeutics (NASDAQ:DNTH) has an average "Moderate Buy" rating from 14 analysts, with a 12-month average price target of $117.82. The stock is currently trading near its 52-week high of $107.99, having risen significantly from its 52-week low. Despite recent insider selling, the company's …

THRM SEC Filings - Gentherm 10-K, 10-Q, 8-K Forms

This page provides a comprehensive overview of Gentherm's (THRM) SEC filings, including annual, quarterly, and material event reports, as well as insider trading forms. It features AI-generated summaries, impact scoring, and sentiment analysis for each filing. Recent filings highlight passive investment disclosures, a new …

Gentherm acquires Innovative Medical Equipment to expand medical portfolio

Gentherm (NASDAQ: THRM) has acquired Innovative Medical Equipment, LLC (IME), a Cleveland-area provider of the ThermaZone thermal therapy device. This acquisition is a strategic move to strengthen Gentherm's Medical business and expand its product portfolio, although the financial terms of the transaction were not …

LightInTheBox Holding Co Ltd (LITB) Risk Assessment: Volatility, Financial Risk & Investment Risk

LightInTheBox Holding Co Ltd (LITB) has a current risk assessment score of 1.64, placing it 34th out of 36 in the Textiles & Apparel industry. The company's stock exhibits a negative beta of -0.10, suggesting it tends to underperform during market upturns but decline …

Walleye Capital LLC Has $12.89 Million Position in Dianthus Therapeutics, Inc. $DNTH

Walleye Capital LLC reduced its stake in Dianthus Therapeutics (NASDAQ:DNTH) by 25.4% in the first quarter, holding 153,585 shares valued at $12.89 million. Despite this, other institutional investors have acquired new positions in the company. Insider selling has also been noted, with SVP Adam …

BRNS|Barinthus Biotherapeutics PLC|Price:0.602|Chg%:-0.007

Barinthus Biotherapeutics PLC (BRNS) is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The company's stock is currently priced at $0.602, with its valuation considered fairly valued among biotechnology peers, and analysts rate it as a "Buy" …

Gentherm (THRM) Could Be 39% Below Fair Value As Earnings Lift Interest